摘要
Breast cancer is the second most common type of cancer and the leading cause of cancer death in women worldwide. Adjuvant tamoxifen therapy significantly slows down estrogen receptor （ER）-positive breast cancer progression, prolongs diseasefree survival, and contributes to the decrease in breast cancer mortality （Musgrove and Sutherland, 2009）. However, majority of the death from breast cancer is due to metastasis that is resistant to therapy （Musgrove and Sutherland, 2009）.
基金
Supplementary material is available at Journal of Molecular Cell Biology online. We thank Drs Mien-Chie Hung （M. D. Anderson Cancer Center）, Kou-Juey Wu （National Yang-Ming University）, and Jeong Hoon Kim （Sungkyunkwan University） for sharing reagents. This work was supported by National Basic Research Program of China （2010CB912102 and 2010CB529703） and National Natural Science Foundation of China （31190061 and 31371408）. G.G. is SA-SIBS scholar.
